Skip to content

Vir Biotechnology, Inc.

VIR· NasdaqCore metricsCIK 1706431

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -7.85%
Market cap
$2.07B
171.27M shares
Filings
811
-$188.00K
Q3 2026−7.6% FY25 yoy
-$96.25M
Q3 2026N/M FY25 yoy
-$104.66M
Q3 2026N/M FY25 yoy
-$115.60M
Q3 2026derivedN/M FY25 yoy
-$0.57
Q3 2026N/M FY25 yoy
$218.87M
Q3 2026+4.1% FY25 yoy
$2.07B
—
6.8×
2.3×
-6.85%
—

Twelve months to Sep 30, 2026 · derived

Price

$12.09+111.36%+$6.37past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$68.56MFY 2025
$1.62B0FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$68,556,000reported
FY 20242024-12-31$74,205,000reported
FY 20232023-12-31$86,180,000reported
FY 20222022-12-31$1,615,797,000reported
FY 20212021-12-31$1,095,415,000reported
FY 20202020-12-31$76,368,000reported
FY 20192019-12-31$8,091,000reported
FY 20182018-12-31$10,668,000reported
FY 20172017-12-31$2,708,000reported

Segments

Products
Revenue by Products, FY2018 to FY2025FY2018Contract Revenue · FY2018 · $868.00KFY2019Contract Revenue · FY2019 · $711.00KFY2020Contract Revenue · FY2020 · $44.50MLicense · FY2020 · $22.75MFY2021Profit-sharing amount · FY2021 · $917.19MCollaboration revenue · FY2021 · $917.19MContract Revenue · FY2021 · $169.87MFY2022Profit-sharing amount · FY2022 · $1.88BCollaboration revenue · FY2022 · $1.51BContract Revenue · FY2022 · $52.71MLicense · FY2022 · $22.29MFY2023Profit-sharing amount previously constrained, released · FY2023 · $35.70MLicense and collaboration revenue · FY2023 · $37.27MProfit-sharing amount · FY2023 · $1.54MCollaboration revenue · FY2023 · $37.27MFY2024License and collaboration revenue · FY2024 · $8.38MProfit-sharing amount · FY2024 · $9.08MCollaboration revenue · FY2024 · $8.38MFY2025
LineFY2025ShareChange
Profit-sharing amount constrained$0.00—N/M
Profit-sharing amount previously constrained, released$0.00——
License and collaboration revenue-$1.14M—N/M
Profit-sharing amount-$1.14M—N/M
Collaboration revenue———
Contract Revenue———
License———
Total$68.56M

From the 10-K filed Feb 23, 2026VIR

Biological products, except diagnostic substances

Vir Biotechnology, Inc. is the 39th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Vir Biotechnology, Inc. · CIK 1706431 · Engraved from SEC EDGAR